Primary Sjögren's syndrome is an autoimmune disease where B cells are overactive. The JAK-STAT signaling pathway, known for its role in other autoimmune diseases, also plays a key part in pSS by activating B cells. Specific proteins in this pathway, like STAT1, STAT3, and STAT5, are involved in the development of pSS. Inhibitors of Janus kinases could be a potential treatment for pSS, improving the quality of life and prognosis for patients.